{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:32:04Z","timestamp":1782603124678,"version":"3.54.5"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010451","name":"Health and Family Planning Commission of Hunan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010451","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2020.00542","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T04:47:19Z","timestamp":1598590039000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["A Multicenter Retrospective Study of 58 Patients With Primary Thyroid Diffuse Large B Cell Lymphoma"],"prefix":"10.3389","volume":"11","author":[{"given":"Jianing","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingyong","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanjia","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peizhi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"key":"B1","first-page":"316","article-title":"Primary thyroid lymphoma","volume":"26","author":"Ansell","year":"1999","journal-title":"Semin Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.4174\/astr.2015.89.6.295","article-title":"Clinicopathological characteristics and treatment outcomes of 38 cases of primary thyroid lymphoma: a multicenter study","volume":"89","author":"Chai","year":"2015","journal-title":"Ann Surg Treat Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.surg.2009.09.020","article-title":"Prognosis of primary thyroid lymphoma: demographic, clinical, and pathologic predictors of survival in 1,408 cases","volume":"146","author":"Graff-Baker","year":"2009","journal-title":"Surgery"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Green","year":"2012","journal-title":"J Clin Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1600-0609.2012.01778.x","article-title":"High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy","volume":"88","author":"Li","year":"2012","journal-title":"Eur J Haematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1038\/leu.2012.83","article-title":"Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the international DLBCL rituximab-CHOP consortium program study","volume":"26","author":"Visco","year":"2012","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1016\/j.suronc.2010.06.002","article-title":"Primary thyroid lymphoma (correction of lympoma): diagnostic and therapeutic dilemmas","volume":"19","author":"Sakorafas","year":"2010","journal-title":"Surg Oncol."},{"key":"B8","first-page":"1","article-title":"The current management of thyroid cancer","volume":"33","author":"Udelsman","year":"1999","journal-title":"Adv Surg"},{"key":"B9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/BF02067333","article-title":"Non-hodgkin's lymphoma of the thyroid: is more than biopsy necessary?","volume":"16","author":"Pyke","year":"1992","journal-title":"World J. Surg."},{"key":"B10","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3109\/10428194.2011.555888","article-title":"High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an international extranodal lymphoma study group and intergruppo italiano linfomi study","volume":"52","author":"Mian","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"B11","first-page":"200","article-title":"Thyroid lymphoma. The case for combined modality therapy","volume":"73","author":"Doria","year":"1994","journal-title":"Cancer Am Cancer Soc."},{"key":"B12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1089\/thy.1993.3.93","article-title":"Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases","volume":"3","author":"Matsuzuka","year":"1993","journal-title":"Thyroid"},{"key":"B13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/annonc\/mdq310","article-title":"Treatment results and prognostic factors in primary thyroid lymphoma patients: a rare cancer network study","volume":"22","author":"Onal","year":"2011","journal-title":"Ann Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e4088","DOI":"10.7759\/cureus.4088","article-title":"Primary thyroid lymphoma: an analysis of the national cancer database","volume":"11","author":"Vardell","year":"2019","journal-title":"Cureus"},{"key":"B15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00423-013-1057-6","article-title":"German association of endocrine surgeons practice guideline for the surgical management of malignant thyroid tumors","volume":"398","author":"Dralle","year":"2013","journal-title":"Langenbecks Arch Surg"},{"key":"B16","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1089\/thy.2013.0523","article-title":"Rituximab-including combined modality treatment for primary thyroid lymphoma: an effective regimen for elderly patients","volume":"24","author":"Watanabe","year":"2014","journal-title":"Thyroid"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMra0807082","article-title":"Aggressive lymphomas","volume":"362","author":"Lenz","year":"2010","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/318533a0","article-title":"The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice","volume":"318","author":"Adams","year":"1985","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","article-title":"MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma","volume":"121","author":"Horn","year":"2013","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the international DLBCL rituximab-CHOP consortium program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"key":"B21","volume-title":"Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4","author":"Swerdlow","year":"2017"},{"key":"B22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1600-0609.2010.01467.x","article-title":"Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP","volume":"85","author":"Yoon","year":"2010","journal-title":"Eur J Haematol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1385\/MO:18:1:15","article-title":"Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma","volume":"18","author":"Llanos","year":"2001","journal-title":"Med Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/bjh.12753","article-title":"A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era","volume":"165","author":"Hosein","year":"2014","journal-title":"Br J Haematol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4930","DOI":"10.1182\/blood-2006-09-047068","article-title":"Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy","volume":"109","author":"Nyman","year":"2007","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/bjh.12488","article-title":"A phase I\/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas","volume":"163","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1097\/00001622-199210000-00007","article-title":"Prognostic factors in non-hodgkin's lymphoma","volume":"4","author":"Shipp","year":"1992","journal-title":"Curr Opin Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1007\/s002680010159","article-title":"Hashimoto's disease and thyroid lymphoma: role of the surgeon","volume":"24","author":"Pasieka","year":"2000","journal-title":"World J Surg."}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00542\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T04:47:22Z","timestamp":1598590042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00542\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":29,"alternative-id":["10.3389\/fendo.2020.00542"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2020.00542","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,28]]},"article-number":"542"}}